ESGO 2025 Preview: Highlights in Gynecologic Oncology to Watch

ESGO 2025 at a Glance

Get ready for ESGO 2025 in Rome. LucidQuest highlights the key scientific priorities in gynecologic oncology and emerging applications of AI and machine learning.

📅 Build your schedule around the topics that interest you. 📥 Download the ESGO 2025_Preview_by_LucidQuest

Dive deeper

Ask Google AI

Ask ChatGPT

Ask Perplexity

Ask Grok

Key Topics From ESGO 2025 Scientific Presentations

Ovarian Cancer

• MIRASOL positions MIRV as new standard for FRα+ platinum-resistant cases.

• SBRT yields 55.9% complete response in oligometastatic disease. 🧬

Genomic Insights

• 894 survival genes in HGSOC.

• POLMs show TP53/PTEN mutations.

• Surufatinib + toripalimab hold promise in recurrent clear cell carcinoma. 🩺

Cervical Cancer

• Fertility-sparing, immunotherapy, and HPV self-sampling (Qiagen: 75.8% sensitivity, Evalyn: 71.8% specificity).

• Preop VMAT/IMRT + surgery = 78% DFS. 🎯

Endometrial Cancer

• Dostarlimab + chemo from RUBY boosts survival in advanced disease.

• EUGENIE highlights p53-aberrant tumors’ worse prognosis. 📈

Personalized Surgery & Survivorship

• ETERNITY shows 19.7% pregnancy with fertility-sparing.

• Tailored ERAS helps older patients.

• LETSGO model improves QoL. 🩺

Uterine Sarcomas & Breast Cancer

• ROCSAN genomic profiling aids survival.

• Gemcitabine–pazopanib moderate in carcinosarcoma.

• Risk-adapted endocrine therapy boosts HR+ BC outcomes. 🔬

Gestational Trophoblastic Tumors & HPV

• TROPHAMET (avelumab + methotrexate) hits 96.2% cure in low-risk GTT.

• Papilocare intensification strengthens HR-HPV clearance. 🦠

Artificial Intelligence and Machine Learning at ESGO 2025

AI in Diagnostics

• ML outperforms standard models in endometrial recurrence.

• Matches IOTA-ADNEX for ovarian classification.

• Refines VTE/AKI prediction. 🤖

AI in Surgery

• Robotic error detection (71% accuracy), perfect Fagotti Score (100%).

• Automated SLN mapping lowers missed nodes. 🩺

AI in Personalized Treatment

• Tumor stroma–rich tumors fare worse (24 vs. 38 months).

• Digital PCR & ML find TP53/KRAS mutations, guiding therapy. 🔬

AI in Guidelines

• SLM/ChatGPT-4 show 75–86% concordance.

• 85% of doctors embrace AI for decision-making. 💡

AI in Screening & Access

• TeleOTIVA (89.7% accuracy) extends cervical screening.

• AI-guided fertility counseling ties natural conception to better DFS (p < 0.005). 🤰